Years of narrow gross margins and perhaps a bloated overhead structure had placed MusclePharm in a perilous working capital position.

FORBES: Blast Off Time For MusclePharm: $12 Million Offer is Complete

We are also working with our banking partners and bondholders to ensure we have a capital structure that will enable Suntech to be successful in the current challenging industry environment.

FORBES: Suntech Q3 Revs Miss; Italian Solar Scandal Spurs Restatement